Adaptimmune Therapeutics (ADAP) has released an update.
Adaptimmune Therapeutics plc announced that the FDA has accepted for priority review its Biologics License Application for afami-cel, a T-cell therapy for advanced synovial sarcoma, with a PDUFA target action date of August 4, 2024.
For further insights into ADAP stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
